Roche says sefaxersen significantly reduces proteinuria in Phase III IgA nephropathy study

Roche says its drug sefaxersen significantly reduced proteinuria in a Phase III study in IgA nephropathy, a kidney disease with few approved treatments. The result is a late-stage efficacy readout for a pipeline asset.

Detected & updated continuously · Source: Nebula